

Interim Clinical Commissioning Policy: Labiaplasty, Vaginoplasty and Hymenorrhaphy

Agreed: November 2013

Ref: N-SC/023











Interim Clinical Commissioning Policy

Labiaplasty, Vaginoplasty and Hymenorrhaphy

First published: November 2013

Prepared by Armed Forces Commissioning Policy Task and Finish Group

Published by NHS England in electronic format only

Gateway Reference: 00599

Contents

Policy Statement	4
Equality Statement	4
Plain Language Summary	4
1. Introduction	4
2. Criteria for commissioning	5
3. Evidence Base	

Policy Statement

NHS England will commission Labiaplasty, Vaginoplasty and Hymenorrhaphy in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for patients where NHS England directly commissions this service.

Equality Statement

NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. NHS England is committed to ensuring equality of access and non-discrimination, irrespective of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex (gender) or sexual orientation. In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which they are responsible, including policy development, review and implementation.

Plain Language Summary

Labiaplasty is a surgery procedure involving the labia.

Vaginoplasty is a surgical procedure involves the creation or reshaping of the vagina. Hymenorrhaphy or hymen reconstruction surgery is the surgical restoration of the hymen.

1. Introduction

Labiaplasty and Vaginoplasty are regarded as procedures of low clinical priority and therefore not routinely funded by the Commissioner.

Hymenorrhaphy, or hymen reconstruction surgery, is a cosmetic procedure and is not routinely funded by the Commissioner.

2. Criteria for commissioning

Labiaplasty

Labiaplasty is generally a cosmetic procedure to change appearance alone and is not routinely funded. Requests for Labiaplasty will be considered for the following indications:

- Where the labia are directly contributing to recurrent disease or infection,
- Where repair of the labia is required after trauma.

Vaginoplasty

Non-reconstructive vaginoplasty or "vaginal rejuvenation" is used to restore vaginal tone and appearance and is not routinely funded. Requests for Vaginoplasty will be considered for the following indications:

- Congenital absence or significant developmental/endocrine abnormalities of the vaginal canal,
- Where repair of the vaginal canal is required after trauma.

Hymenorrhaphy

Hymenorrhaphy, or hymen reconstruction surgery, is a cosmetic procedure and is not routinely funded.

Gender Dysphoria

This policy does not apply to genital reconstruction for gender dysphoria which is currently being established by the Gender Identity Services Clinical Reference Group - http://www.england.nhs.uk/resources/spec-comm-resources/npc-crg/group-c/c05/

The Clinician proposing this intervention is required to secure Prior Approval from the Armed Forces Commissioning or Health & Justice Commissioning Team in their area

(Application form and contact details can be found on NHS Internet

http://www.england.nhs.uk/ourwork/d-com/policies/ssp/)

3. Evidence Base

These procedures are considered to be of limited clinical value.